These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 15589605)

  • 1. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
    J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
    Beiner ME; Finch A; Rosen B; Lubinski J; Moller P; Ghadirian P; Lynch HT; Friedman E; Sun P; Narod SA;
    Gynecol Oncol; 2007 Jan; 104(1):7-10. PubMed ID: 16962648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
    Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
    Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
    Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA
    Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.